Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 4, 2011, Pages 709-712

  Wirden, Marc ^a   Soulie, Cathia ^a   Valantin, Marc Antoine ^a   Fourati, Slim ^a   Simon, Anne ^a   Lambert Niclot, Sidonie ^a   Bonmarchand, Manuela ^a   Clavel Osorio, Cyril ^a   Marcelin, Anne Genevieve ^a   Katlama, Christine ^a   Calvez, Vincent ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

HIV DNA; Resistance genotyping; Resistance mutations

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROVIRAL DNA; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS RNA;

ADOLESCENT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EXPOSURE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MAJOR CLINICAL STUDY; NONHUMAN; PRESCHOOL CHILD; RESIDUAL VIREMIA; REVERSE TRANSCRIPTION; RNA SEQUENCE; SCHOOL CHILD; SUPPRESSED VIREMIA; VIREMIA; VIRUS GENE; VIRUS MUTATION; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV; HIV INFECTIONS; HUMANS; LYMPHOCYTES; MICROBIAL SENSITIVITY TESTS; PLASMA; PROVIRUSES; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; VIREMIA; VIROLOGY;

EID: 79952812127     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq544     Document Type: Article

References (9)

1. Hirsch MS, Gunthard HF, Schapiro JM et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008; 47: 266-85.
2. Pascual-Pareja JF, Martinez-Prats L, Luczkowiak J et al. Detection of HIV-1 at between 20 and 49 copies per milliliter by the Cobas TaqMan HIV-1 v2.0 assay is associated with higher pretherapy viral load and less time on antiretroviral therapy. J Clin Microbiol 2010; 48: 1911-2.
3. Thompson MA, Aberg JA, Cahn P et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304: 321-33.
4. Marcello A. Latency: the hidden HIV-1 challenge. Retrovirology 2006; 3: 7.
5. Mavigner M, Delobel P, Cazabat M et al. HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy. PLoS One 2009; 4: e7658.
6. Wirden M, Delaugerre C, Marcelin AG et al. Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapy. Antimicrob Agents Chemother 2004; 48: 644-7.
7. Delaugerre C, Charreau I, Braun J et al. HIV-1 genotypic resistance tests performed in cellular DNA are less informative than those collected from previous plasma RNAs in treatment experienced patients with suppressed viremia: a sub-study of EASIER-ANRS 138 trial. In: Abstracts of the Seventeenth Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, 2010. Abstract 573, p. 273. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
8. Brennan TP, Woods JO, Sedaghat AR et al. Analysis of human immunodeficiency virus type 1 viremia and provirus in resting CD4+ T cells reveals a novel source of residual viremia in patients on antiretroviral therapy. J Virol 2009; 83: 8470-81.
9. Wang C, Mitsuya Y, Gharizadeh B et al. Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. Genome Res 2007; 17: 1195-201.